INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL), Neurocrine (NBIX) and I...

Current Quarter	$NA	Next Quarter	$NA
Current Year	$NA	Next Year	$NA
QoQ Growth	NaN%	YoY Growth	NaN%
3Y EPS CAGR	-3.9%	Target Price	$7.00
Consensus	Buy	Upside	+438.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INMB	$1.30	+2.36%	312.37K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INMB	$1.30	+2.4%	312.37K
3
4
5
6

INMB

INMB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get INmune Bio Inc. Data in Excel

Get INmune Bio Inc. Data in Excel